secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001140361-26-017275
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharmaceuticals sells Rare Pediatric Disease PRV for $180M, extending cash runway to Q2 2028
--------------------------------------------------------------------------------

- Enters definitive agreement to sell PRV for $180M in cash; closing subject to HSR antitrust waiting period.
- PRV was awarded following FDA accelerated approval of KRESLADI (marnetegragene autotemcel) for LAD-I.
- Non-dilutive capital to support cardiovascular pipeline: Danon disease, PKP2-ACM, BAG3-DCM programs.
- Cash runway extended into second quarter of 2028, per CEO Gaurav Shah.
- PRV program reauthorized in February 2026, reinforcing incentive for rare pediatric disease therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036126017275/0001140361-26-017275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036126017275/ef20071574_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-017275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer